A rational approach to the treatment of hypertension in special populations

American Family Physician

Volumn 60, Issue 1, 1999, Pages 156-162

  Hall, W Dallas ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; SILDENAFIL;

AGED; AGING; ANTIHYPERTENSIVE THERAPY; CLINICAL PROTOCOL; DIET; DRUG CHOICE; HUMAN; HYPERTENSION; LIFESTYLE; NEGRO; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC HYPERTENSION; TREATMENT PLANNING;

AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIASTOLE; DIURETICS; HUMANS; HYPERTENSION; LIFE STYLE; MIDDLE AGED; SYSTOLE;

EID: 0344780862     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46 [Published erratum in Arch Intern Med 1998;158:573].
2. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13.
3. Hall WD. Cardiovascular therapy in black patients. In: Messerli FH, ed. Cardiovascular drug therapy. 2d ed. Philadelphia: Saunders, 1996:280-91.
4. Aloia JF, Vaswani A, Ma R, Flaster E. Sodium distribution in black and white women. Miner Electrolyte Metab 1997;23:74-8.
5. Cho JH, Nash F, Fekete Z, Kimura M, Reeves JP, Aviv A. Increased calcium stores in platelets from African Americans. Hypertension 1995;25:377-83.
6. Whelton PK, Appel U, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998;279:839-46 [Published erratum in JAMA 1998;279:1954].
7. Matlou SM, Isles CG, Higgs A, Milne FJ, Murray GD, Schultz E, et al. Potassium supplementation in blacks with mild to moderate essential hypertension. J Hypertens 1986;4:61-4.
8. Sowers JR, Zemel MB, Zemel P, Beck FW, Walsh MF, Zawada ET. Salt sensitivity in blacks. Salt intake and natriuretic substances. Hypertension 1988;12:485-90.
9. Kumanyika SK, Cutler JA. Dietary sodium reduction: is there cause for concern? J Am Coll Nutr 1997;16:192-203.
10. Laragh JH, Cannon PJ, Stason WB, Heinemann HO. Physiologic and clinical observations on furosemide and ethacrynic acid. Ann N Y Acad Sci 1966; 139:453-65.
11. Hall WD, Israili ZI. The use of ACE inhibitors in blacks and whites. In: Schachter M, ed. ACE inhibitors: current use and future prospects. London: Dunitz, 1995:123-43.
12. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-13.
13. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998;31:1088-96.
14. Moser M, Prisant LM. Low-dose combination therapy in hypertension [Editorial], Am Fam Physician 1997;56:1275-6,1279, 1282.
15. Materson BJ. Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Am J Hypertens 1995;8(12 pt 2):91S-3S.
16. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
17. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
18. Implications of the Systolic Hypertension in the Elderly Program. Hypertension 1993;21:335-43.
19. Palmer RM, Osterweil D, Loon-Lustig G, Stern N. The effect of dietary salt ingestion on blood pressure of old-old subjects. A double-blind, placebo-controlled, crossover trial. J Am Geriatr Soc 1989;37:931-6.
20. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994;272:1932-8.
21. Hall WD. Management of systolic hypertension in the elderly. Semin Nephrol 1996;16:299-308.
22. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-7.
23. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
24. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
25. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
26. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
27. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
28. Kaplan N. J-curve not burned off by HOT study. Lancet 1998;351:1748-9.
29. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38. BMJ 1998;317:703-13.
30. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92 [Published erratum in JAMA 1997;277:1356].
31. Duchier J, Iannascoli F, Safar M. Antihypertensive effect of sustained-release isosorbide dinitrate for isolated systolic systemic hypertension in the elderly. Am J Cardiol 1987;60:99-102.
32. Starmans-Kool MJ, Kleinjans HA, Lustermans FA, Kragten JA, Breed JG, Van Bortel LM. Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. J Hum Hypertens 1998;12:557-61.
33. Sildenafil: an oral drug for impotence. Med Lett Drugs Ther 1998;40:51-2.